Catalent FDA write-up ‘allegedly’ the culprit behind Novo Nordisk’s Wegovy supply woes: report

Catalent received an FDA write-up for its syringe filling facility in Belgium, BioProcess International reports, adding that it is “allegedly” the culprit behind supply challenges for Novo Nordisk’s obesity med Wegovy.

An FDA inspection of the CDMO’s filling site in Brussels yielded a Form…